ERBB2 and breast carcinoma: To further examine the sensitivities of NF1 deficient tumors in a more clinically relevant context, we treated a HER2 + NF1 null patient-derived xenograft (PDX) model derived from a patient with trastuzumab-refractory breast cancer with trastuzumab, trametinib, or the combination.